Key Takeaways, With Data for Maryland FDA approvals vary by drug: There are currently three GLP-1s on the market that the FDA ...

Researchers have achieved impressive results in animal studies with a new weight-loss drug that has no GLP-1-style side ...

Merck (MRK) secured exclusive rights to develop and sell an oral weight loss drug under a license deal with Hansoh Pharma that could fetch the Chinese biopharmaceutical company up to $2 billion. Merck ...

Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...

The US data suggest that the South has seen the greatest shifts, and the highest rate of GLP-1 prescribing per capita.

Blood sugar and insulin levels also depend on the vagus nerve. As blood sugar levels rise, the vagus nerve stimulates the ...

Researchers have discovered that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor ...

Newer glucose-lowering drugs reduce the risk for late-onset seizures and epilepsy by 24%, with GLP-1 RAs cutting the risk by ...

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic ...

Shares of Viking Therapeutics (VKTX) are down $2.70, or 6%, to $44.00 in pre-market trading following Merck (MRK) and Chinese biopharmaceutical ...

Construction has already begun on the Ozempic-producer’s new Danish production facility and 40,000m² warehouse.